Featured Content
HHS Reissues Disputed 340B Policy on Orphan-drug Discounts
(Modern Healthcare) July 21, 2014 - HHS issued an interpretive rule (PDF) that requires drug companies to provide discounts on orphan drugs sold through a federal program just months after a judge struck down the government's previous version of the rule.
Commentary: The 340 B program continues to be yet another runaway train in the cancer care delivery system. With approximately...
 |
Our free daily oncology focused e-news service.
Subscribe» | Search Archives» |
Today's News
New View of Stomach Cancer Could Hasten Better Therapies
(Dana-Farber) July 23, 2014 - In a massive effort to catalog the molecular causes of stomach cancer, scientists, including researchers from Dana-Farber Cancer Institute, have identified four subtypes of tumors based on shared mutations and other molecular abnormalities.
read press release »
Surgical Robot Fails to Show Advantages in Treating Bladder Cancer
(Wall Street Journal) July 23, 2014 - A new study finds treating bladder cancer with a surgical robot made by Intuitive Surgical is no better at reducing procedural complications than performing the procedure with traditional surgery, a result that surprised researchers, who had expected the robotic technology to be superior to human hands alone.
read article (paid subscription required) »
U.S. Paves Way for Novartis to Copy Amgen Biotech Drug
(Reuters) July 24, 2014 - U.S. regulators have accepted an application by Sandoz - the generics arm of Novartis - seeking approval for a copycat version of Amgen's drug Neupogen, or filgrastim, for patients with low white blood cell counts.
read article »
News Story Commentary By Academic and Community Oncologists
|
Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape. OBR Job BoardSunesis Pharmaceuticals, Inc. has 2 jobs posted. Novocure has posted 4 jobs. |
The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™
View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results
Date: July 22, 2014
Company: Puma Biotechnology
Product: neratinib (PB272)
Date: July 23, 2014
Company: Gilead Inc.
Product: Zydelig (idelalisib)
Date: mid-2014
Company: Threshold Pharmaceuticals / Merck KGaA
Product: TH-302
OBR's Oncology Events Calendar is a compilation of important upcoming conferences and meetings that is updated daily.
Through Aug 1
Through Aug 9
Through Aug 13